{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:59:35Z","timestamp":1790175575612,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01207-1","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:01:24Z","timestamp":1785920484000},"page":"1419-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fc-optimized GITR antibody enhances a CD4 T cell\u2013dendritic cell crosstalk to promote antitumor immunity"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-4892","authenticated-orcid":false,"given":"Yahel","family":"Avraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzlil","family":"Yair Bar-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Toval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviya","family":"Habshush Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Blanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Shapir Itai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-341X","authenticated-orcid":false,"given":"Tali","family":"Feferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8330-1674","authenticated-orcid":false,"given":"Moshe","family":"Biton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-7601","authenticated-orcid":false,"given":"Rony","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"1207_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1207_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1207_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-23-1014","volume":"30","author":"SH Lim","year":"2024","unstructured":"Lim, S. H., Beers, S. A., Al-Shamkhani, A. & Cragg, M. S. Agonist antibodies for cancer immunotherapy: history, hopes, and challenges. Clin. Cancer Res. 30, 1712\u20131723 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrd.2018.75","volume":"17","author":"PA Mayes","year":"2018","unstructured":"Mayes, P. A., Hance, K. W. & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17, 509\u2013527 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/cts.13355","volume":"15","author":"Y Ji","year":"2022","unstructured":"Ji, Y. et al. Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: dose selection based on MABEL and biologically active dose. Clin. Transl. Sci. 15, 2218\u20132229 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"1207_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/2211-5463.13451","volume":"12","author":"Q Tong","year":"2022","unstructured":"Tong, Q. et al. Development of a fully human anti-GITR antibody with potent antitumor activity using H2L2 mice. FEBS Open Bio 12, 1542\u20131557 (2022).","journal-title":"FEBS Open Bio"},{"key":"1207_CR7","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.4049\/jimmunol.1403076","volume":"195","author":"YH Kim","year":"2015","unstructured":"Kim, Y. H. et al. Authentic GITR signaling fails to induce tumor regression unless Foxp3+ regulatory T cells are depleted. J. Immunol. 195, 4721\u20134729 (2015).","journal-title":"J. Immunol."},{"key":"1207_CR8","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-22-0339","volume":"28","author":"D Davar","year":"2022","unstructured":"Davar, D. et al. Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab, or nivolumab in patients with advanced solid tumors. Clin. Cancer Res. 28, 3990\u20134002 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1207_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2023","unstructured":"Galvez-Cancino, F. et al. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat. Rev. Cancer 24, 51\u201371 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1207_CR10","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","volume":"41","author":"JC Osorio","year":"2023","unstructured":"Osorio, J. C., Smith, P., Knorr, D. A. & Ravetch, J. V. The antitumor activities of anti-CD47 antibodies require Fc\u2013Fc\u03b3R interactions. Cancer Cell 41, 2051\u20132065 (2023).","journal-title":"Cancer Cell"},{"key":"1207_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","volume":"29","author":"R Dahan","year":"2016","unstructured":"Dahan, R. et al. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective Fc\u03b3R engagement. Cancer Cell 29, 820\u2013831 (2016).","journal-title":"Cancer Cell"},{"key":"1207_CR12","doi-asserted-by":"publisher","first-page":"eadd8005","DOI":"10.1126\/sciimmunol.add8005","volume":"8","author":"NC Saban","year":"2023","unstructured":"Saban, N. C. et al. Fc glycoengineering of a PD-L1 antibody harnesses Fc\u03b3 receptors for increased antitumor efficacy. Sci. Immunol. 8, eadd8005 (2023).","journal-title":"Sci. Immunol."},{"key":"1207_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"FA Vargas","year":"2018","unstructured":"Vargas, F. A. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649\u2013663 (2018).","journal-title":"Cancer Cell"},{"key":"1207_CR14","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"1207_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/icb.2014.26","volume":"92","author":"Y Bulliard","year":"2014","unstructured":"Bulliard, Y. et al. OX40 engagement depletes intratumoral Tregs via activating Fc\u03b3Rs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475\u2013480 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"1207_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.immuni.2018.09.014","volume":"49","author":"SL Buchan","year":"2018","unstructured":"Buchan, S. L. et al. Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity 49, 958\u2013970 (2018).","journal-title":"Immunity"},{"key":"1207_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","volume":"187","author":"AL White","year":"2011","unstructured":"White, A. L. et al. Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754\u20131763 (2011).","journal-title":"J. Immunol."},{"key":"1207_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1206954","volume":"333","author":"F Li","year":"2011","unstructured":"Li, F. & Ravetch, J. V. Inhibitory Fc\u03b3 receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030\u20131034 (2011).","journal-title":"Science"},{"key":"1207_CR19","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20130573","volume":"210","author":"Y Bulliard","year":"2013","unstructured":"Bulliard, Y. et al. Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685\u20131693 (2013).","journal-title":"J. Exp. Med."},{"key":"1207_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","volume":"7","author":"JO Richards","year":"2008","unstructured":"Richards, J. O. et al. Optimization of antibody binding to Fc\u03b3RIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517\u20132527 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"1207_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/protein\/gzt022","volume":"26","author":"F Mimoto","year":"2013","unstructured":"Mimoto, F. et al. Engineered antibody Fc variant with selectively enhanced Fc\u03b3RIIb binding over both Fc\u03b3RIIaR131 and Fc\u03b3RIIaH131. Protein Eng. Des. Sel. 26, 589\u2013598 (2013).","journal-title":"Protein Eng. Des. Sel."},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1207_CR23","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","volume":"190","author":"A Lux","year":"2013","unstructured":"Lux, A., Yu, X., Scanlan, C. N. & Nimmerjahn, F. Impact of immune complex size and glycosylation on IgG binding to human FcgRs. J. Immunol. 190, 4315\u20134323 (2013).","journal-title":"J. Immunol."},{"key":"1207_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","volume":"588","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588, 485\u2013490 (2020).","journal-title":"Nature"},{"key":"1207_CR25","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733\u201326740 (2002).","journal-title":"J. Biol. Chem."},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","volume":"25","author":"R Zappasodi","year":"2019","unstructured":"Zappasodi, R. et al. Rational design of anti-GITR-based combination immunotherapy. Nat. Med. 25, 759\u2013766 (2019).","journal-title":"Nat. Med."},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-20-2886","volume":"27","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos, K. P. et al. Phase I study of MK-4166, an anti-human glucocorticoid-induced TNF receptor antibody, alone or with pembrolizumab in advanced solid tumors. Clin. Cancer Res. 27, 1904\u20131911 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1207_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100308","volume":"16","author":"N Lakhani","year":"2022","unstructured":"Lakhani, N. et al. 196TiP a phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies. Immuno Oncol. Technol. 16, 100308 (2022).","journal-title":"Immuno Oncol. Technol."},{"key":"1207_CR29","doi-asserted-by":"publisher","first-page":"100784","DOI":"10.1016\/j.esmoop.2023.100784","volume":"8","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. ESMO Open 8, 100784 (2023).","journal-title":"ESMO Open"},{"key":"1207_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002863","volume":"9","author":"SA Piha-Paul","year":"2021","unstructured":"Piha-Paul, S. A. et al. First-in-human phase I\/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. J. Immunother. Cancer 9, e002863 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1207_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0407-x","volume":"6","author":"B Tran","year":"2018","unstructured":"Tran, B. et al. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J. Immunother. Cancer 6, 1\u20139 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1207_CR32","doi-asserted-by":"publisher","first-page":"vii69","DOI":"10.1093\/neuonc\/noac209.267","volume":"24","author":"S Bagley","year":"2022","unstructured":"Bagley, S. et al. CTIM-35. A phase II study of GITR agonist INCAGN01876 and PD-1 inhibitor retifanlimab in combination with stereotactic radiotherapy in patients with recurrent glioblastoma. Neuro Oncol. 24, vii69 (2022).","journal-title":"Neuro Oncol."},{"key":"1207_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, 1\u201320 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1207_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","volume":"23","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn, F. et al. Fc\u03b3RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41\u201351 (2005).","journal-title":"Immunity"},{"key":"1207_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.molimm.2014.09.017","volume":"63","author":"E Arduin","year":"2015","unstructured":"Arduin, E. et al. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A\/L235A and N297A Fc mutations engineered into mouse IgG2a. Mol. Immunol. 63, 456\u2013463 (2015).","journal-title":"Mol. Immunol."},{"key":"1207_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.adg1487","volume":"8","author":"AG Dykema","year":"2023","unstructured":"Dykema, A. G. et al. Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci. Immunol. 8, 1\u201316 (2023).","journal-title":"Sci. Immunol."},{"key":"1207_CR37","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.immuni.2025.03.021","volume":"58","author":"F Galvez-Cancino","year":"2025","unstructured":"Galvez-Cancino, F. et al. Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. Immunity 58, 1236\u20131253 (2025).","journal-title":"Immunity"},{"key":"1207_CR38","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20112675","volume":"209","author":"MM Meredith","year":"2012","unstructured":"Meredith, M. M. et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J. Exp. Med. 209, 1153\u20131165 (2012).","journal-title":"J. Exp. Med."},{"key":"1207_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","volume":"3","author":"R Salomon","year":"2022","unstructured":"Salomon, R. et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat. Cancer 3, 287\u2013302 (2022).","journal-title":"Nat. Cancer"},{"key":"1207_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","volume":"56","author":"M Zagorulya","year":"2023","unstructured":"Zagorulya, M. et al. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Immunity 56, 386\u2013405 (2023).","journal-title":"Immunity"},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I. et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. Cancer 1, 1153\u20131166 (2020).","journal-title":"Nat. Cancer"},{"key":"1207_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577\u2013586 (2017).","journal-title":"Immunity"},{"key":"1207_CR43","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","volume":"81","author":"JR Campbell","year":"2021","unstructured":"Campbell, J. R. et al. Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models. Cancer Res. 81, 2983\u20132994 (2021).","journal-title":"Cancer Res."},{"key":"1207_CR44","doi-asserted-by":"publisher","first-page":"2141007","DOI":"10.1080\/2162402X.2022.2141007","volume":"11","author":"JD Weaver","year":"2022","unstructured":"Weaver, J. D. et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology 11, 2141007 (2022).","journal-title":"Oncoimmunology"},{"key":"1207_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1150149","volume":"13","author":"L Pousse","year":"2023","unstructured":"Pousse, L. et al. CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia. Front. Oncol. 13, 1150149 (2023).","journal-title":"Front. Oncol."},{"key":"1207_CR46","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","volume":"14","author":"D Chand","year":"2024","unstructured":"Chand, D. et al. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy. Cancer Discov. 14, 2407\u20132429 (2024).","journal-title":"Cancer Discov."},{"key":"1207_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","volume":"33","author":"JD Waight","year":"2018","unstructured":"Waight, J. D. et al. Selective Fc\u03b3R co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell 33, 1033\u20131047 (2018).","journal-title":"Cancer Cell"},{"key":"1207_CR48","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"1207_CR49","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh, D. Y. & Fong, L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity 54, 2701\u20132711 (2021).","journal-title":"Immunity"},{"key":"1207_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm4552","volume":"8","author":"C He","year":"2022","unstructured":"He, C. et al. Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Sci. Adv. 8, 4552 (2022).","journal-title":"Sci. Adv."},{"key":"1207_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman, R. M. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30, 1\u201322 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"1207_CR52","doi-asserted-by":"publisher","first-page":"eabg2752","DOI":"10.1126\/science.abg2752","volume":"379","author":"M He","year":"2023","unstructured":"He, M. et al. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science 379, eabg2752 (2023).","journal-title":"Science"},{"key":"1207_CR53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105323118","volume":"118","author":"WW Ho","year":"2021","unstructured":"Ho, W. W. et al. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc. Natl Acad. Sci. USA 118, e2105323118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1207_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai, Y. et al. Bispecific dendritic\u2013T cell engager potentiates anti-tumor immunity. Cell 187, 375\u2013389 (2024).","journal-title":"Cell"},{"key":"1207_CR55","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","volume":"584","author":"ST Ferris","year":"2020","unstructured":"Ferris, S. T. et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584, 624\u2013629 (2020).","journal-title":"Nature"},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nmeth762","volume":"2","author":"T Buch","year":"2005","unstructured":"Buch, T. et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat. Methods 2, 419\u2013426 (2005).","journal-title":"Nat. Methods"},{"key":"1207_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba1896","volume":"5","author":"C Wohn","year":"2020","unstructured":"Wohn, C. et al. Absence of MHC class II on cDC1 dendritic cells triggers fatal autoimmunity to a cross-presented self-antigen. Sci. Immunol. 5, 1896 (2020).","journal-title":"Sci. Immunol."},{"key":"1207_CR58","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","volume":"108","author":"W Schaefer","year":"2011","unstructured":"Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl Acad. Sci. USA 108, 11187\u201311192 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1207_CR59","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677\u2013681 (1998).","journal-title":"Nat. Biotechnol."},{"key":"1207_CR60","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ni.2587","volume":"14","author":"V Jojic","year":"2013","unstructured":"Jojic, V. et al. Identification of transcriptional regulators in the mouse immune system. Nat. Immunol. 14, 633\u2013643 (2013).","journal-title":"Nat. Immunol."},{"key":"1207_CR61","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. UCell: robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796\u20133798 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1207_CR62","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"1207_CR63","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01207-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:02:11Z","timestamp":1790172131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01207-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01207-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Weizmann Institute has filed a Patent Cooperation Treaty patent application related to this work, on which R.D. and Y.A. are inventors. R.D. serves as a consultant and received research grant support from Teva Pharmaceuticals Industries related to this study. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}